BRNS — Barinthus Biotherapeutics Balance Sheet
0.000.00%
- $55.06m
- -$50.87m
- $0.80m
- 13
- 46
- 15
- 12
Annual balance sheet for Barinthus Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 11.4 | 43.3 | 214 | 194 | 142 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.91 | 3.23 | 6.95 | 10.4 | 7.94 |
| Prepaid Expenses | |||||
| Total Current Assets | 16.2 | 47.9 | 227 | 213 | 157 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.79 | 2.76 | 9.09 | 15.7 | 19.4 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 19 | 50.7 | 281 | 270 | 215 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.75 | 7.64 | 11.2 | 12.2 | 12.6 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7.72 | 54.2 | 28.6 | 27.3 | 27.7 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 11.3 | -3.54 | 252 | 243 | 187 |
| Total Liabilities & Shareholders' Equity | 19 | 50.7 | 281 | 270 | 215 |
| Total Common Shares Outstanding |